AstraZeneca’s Pegasus Study of Brilinta Drug Shows Positive Results

March 16, 2015 2:10 PM

4 0

AstraZeneca’s Pegasus Study of Brilinta Drug Shows Positive Results

Results from the Pegasus study of AstraZeneca’s (LON:AZN) Brilinta drug found that it could extend patients’ lives following a heart attack.

The study investigated Brilinta (ticagrelor) tablets plus low dose aspirin, compared to placebo plus low dose aspirin, for the chronic secondary prevention of atherothrombotic events in patients who had a Myocardial Infarction one to three years prior to study enrolment.

Read more

To category page

Loading...